{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:59:39Z","timestamp":1790881179937,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aims to identify programmed cell death (PCD)-associated genes linked to breast cancer prognosis for the construction of a prognostic model. Transcriptomic and clinical information was imported from the The Cancer Genome Atlas (TCGA) and GEO databases. Modulatory genes related to 18 types of PCD were evaluated. Furthermore, the TCGA and GEO datasets were employed as the training and validation datasets, respectively. A risk score prognostic model based on PCD-related genes was generated via univariate, LASSO, and multivariate Cox regression analyses. Further, differences in drug sensitivity, tumor mutation burden (TMB), immune-related pathways and cell infiltration, and immune checkpoints were compared between high-risk and low-risk cohorts to elucidate the clinical applicability of the model. Lastly, the model gene\u2019s expression was verified by RT-PCR. The data revealed 1480 PCD-related genes from the TCGA breast cancer gene expression matrix. Differential expression analysis identified 186 differentially expressed PCD genes. Furthermore, a prognostic model was generated according to the risk scores using multivariate Cox regression. The model comprised 8 PCD-related genes (BRSK2, CD24, IFNG, LAMB3, PDX1, PMAIP1, SLC7A11, and TRIML2). Moreover, breast cancer cases were divided into high-risk and low-risk cohorts per the median risk score. The results indicated that low-risk patients had better prognoses, and the model showed good predictive performance in the GEO validation cohort. The area under the curve values were 0.819, 0.731, and 0.674 for the nomogram\u2019s 3, 5, and 8 years overall survival, respectively. Functional enrichment analysis revealed that the prognostic model was markedly linked with the modulation of the immune microenvironment and tumor progression in breast cancer. Immune infiltration assessment revealed that low-risk patients had increased activity in immune-related pathways and infiltration of immune cells. In addition, the low-risk cohort had lower TMB and elevated immune checkpoint-related levels. Correlation analysis between immune checkpoints and risk scores indicated that low-risk patients were more responsive to immunotherapy. Drug sensitivity analysis showed variations in the IC\n                      <jats:sub>50<\/jats:sub>\n                      values between the risk cohorts, suggesting potential variations in drug efficacy across different risk cohorts. Gene expression was verified by RT-PCR.A prognostic risk model for breast cancer based on 8 PCD-related genes was constructed and its predictive value was validated. The established model may provide novel biomarkers and effective therapeutic targets for breast cancer diagnosis and treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049607","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:00:55Z","timestamp":1784919655000},"page":"e49607","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A prognostic risk model based on programmed cell death genes for breast cancer and its potential clinical application"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-8788","authenticated-orcid":false,"given":"Ziran","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Diseases, Jiaxing Women and Children\u2019s Hospital, Wenzhou Medical University, Jiaxing, Zhejiang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Diseases, Jiaxing Women and Children\u2019s Hospital, Wenzhou Medical University, Jiaxing, Zhejiang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Breast Diseases, Jiaxing Women and Children\u2019s Hospital, Wenzhou Medical University, Jiaxing, Zhejiang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Breast Diseases, Jiaxing Women and Children\u2019s Hospital, Wenzhou Medical University, Jiaxing, Zhejiang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Nursing, Jiaxing Women and Children\u2019s Hospital, Wenzhou Medical University, Jiaxing, Zhejiang, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"900","DOI":"10.20892\/j.issn.2095-3941.2020.0523","article-title":"Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030.","volume":"18","author":"Lei","year":"2021","journal-title":"Cancer Biol Med"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness and current knowledge of breast cancer.","volume":"50","author":"Akram","year":"2017","journal-title":"Biol Res"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","article-title":"Breast cancer.","volume":"365","author":"Veronesi","year":"2005","journal-title":"Lancet"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"847345","DOI":"10.3389\/fimmu.2022.847345","article-title":"Programmed cell death tunes tumor immunity.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2407-11-143","article-title":"Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.","volume":"11","author":"Kao","year":"2011","journal-title":"BMC Cancer"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12967-023-04468-x","article-title":"Integrated machine learning survival framework develops a prognostic model based on inter-crosstalk definition of mitochondrial function and cell death patterns in a large multicenter cohort for lower-grade glioma.","volume":"21","author":"Qin","year":"2023","journal-title":"J Transl Med"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection.","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10555-010-9248-x","article-title":"Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.","volume":"29","author":"Markopoulos","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","article-title":"Apoptosis, autophagy, necroptosis, and cancer metastasis.","volume":"14","author":"Su","year":"2015","journal-title":"Mol Cancer"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/OTT.S187280","article-title":"Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-\u03b3-associated JAK-STAT pathway.","volume":"12","author":"Xue","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity.","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1038\/s41598-018-21216-0","article-title":"LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET\/Akt signals.","volume":"8","author":"Jung","year":"2018","journal-title":"Sci Rep"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41419-019-1320-z","article-title":"LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K\/Akt signaling pathway.","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"15903","DOI":"10.1038\/s41598-023-42994-2","article-title":"NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy.","volume":"13","author":"Al Shboul","year":"2023","journal-title":"Sci Rep"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-021-04415-y","article-title":"The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.","volume":"12","author":"Karbon","year":"2021","journal-title":"Cell Death Dis"},{"key":"R22-20261001","first-page":"263","article-title":"Strong association of ARK5 with tumor invasion and metastasis.","volume":"23","author":"Kusakai","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"44669","DOI":"10.18632\/oncotarget.17965","article-title":"BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.","volume":"8","author":"Saiyin","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1128\/MCB.24.8.3526-3535.2004","article-title":"ARK5 is a tumor invasion-associated factor downstream of Akt signaling.","volume":"24","author":"Suzuki","year":"2004","journal-title":"Mol Cell Biol"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/B:HIJO.0000032357.16261.c5","article-title":"Tumour biological aspects of CD24, a mucin-like adhesion molecule.","volume":"35","author":"Kristiansen","year":"2004","journal-title":"J Mol Histol"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.21037\/atm.2016.03.51","article-title":"PDX1 associated therapy in translational medicine.","volume":"4","author":"Yu","year":"2016","journal-title":"Ann Transl Med"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","article-title":"Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.","volume":"38","author":"Koppula","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1541-7786.MCR-14-0385","article-title":"Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.","volume":"13","author":"Kung","year":"2015","journal-title":"Mol Cancer Res"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"e7522","DOI":"10.7717\/peerj.7522","article-title":"Characterization of ceRNA network to reveal potential prognostic biomarkers in triple-negative breast cancer.","volume":"7","author":"Song","year":"2019","journal-title":"PeerJ"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer.","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis.","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2019.01.011","article-title":"Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer.","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2018.08.009","article-title":"Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma.","volume":"155","author":"Mahajan","year":"2018","journal-title":"Gastroenterology"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2019.09.002","article-title":"Metabolic crosstalk in the breast cancer microenvironment.","volume":"121","author":"Dias","year":"2019","journal-title":"Eur J Cancer"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"643771","DOI":"10.3389\/fimmu.2021.643771","article-title":"Macrophage biology and mechanisms of immune suppression in breast cancer.","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.33009","article-title":"Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer.","volume":"147","author":"Zheng","year":"2020","journal-title":"Int J Cancer"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"106936","DOI":"10.1016\/j.ijsu.2022.106936","article-title":"Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.","volume":"107","author":"Zou","year":"2022","journal-title":"Int J Surg"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10549-010-0942-8","article-title":"CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.","volume":"126","author":"Kmieciak","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-016-3743-x","article-title":"Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.","volume":"156","author":"Matsumoto","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.","volume":"490","year":"2012","journal-title":"Nature"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/humu.10174","article-title":"TP53 and breast cancer.","volume":"21","author":"B\u00f8rresen-Dale","year":"2003","journal-title":"Hum Mutat"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trecan.2020.01.007","article-title":"TP53 mutations and outcomes in breast cancer: reading beyond the headlines.","volume":"6","author":"Shahbandi","year":"2020","journal-title":"Trends Cancer"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/0008-5472.CAN-14-0092","article-title":"Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.","volume":"74","author":"Jiang","year":"2014","journal-title":"Cancer Res"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"20524","DOI":"10.1038\/s41598-022-25059-8","article-title":"Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.","volume":"12","author":"Lv","year":"2022","journal-title":"Sci Rep"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"964118","DOI":"10.3389\/fimmu.2022.964118","article-title":"Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"1325452","DOI":"10.3389\/fonc.2023.1325452","article-title":"Establishment of a lysosome-related prognostic signature in breast cancer to predict immune infiltration and therapy response.","volume":"13","author":"Su","year":"2023","journal-title":"Front Oncol"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"964508","DOI":"10.3389\/fonc.2022.964508","article-title":"A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer.","volume":"12","author":"Zhong","year":"2022","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:02:16Z","timestamp":1790877736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":50,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049607","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2025-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}